Logo

Monica Arnold

Monica Arnold
949.386.7264
monica.arnold@armondwilson.com

Monica Arnold is a trial attorney focused on IP litigation. Her work is technologically diverse, including genetically engineered cell therapies, and small molecule pharmaceuticals. Previously Monica clerked on the U.S. District Court for the Central District of California and was a litigation associate at Milbank LLP in Los Angeles.

Monica earned her B.S. in Neuroscience from the University of California, Los Angeles, where she utilized hydrogen peroxide exposure to the hippocampus to model effects of oxidative stress on synaptic plasticity in that brain region. She then received a Ph.D. in Pharmacology and Toxicology from the University of California, Irvine where her award-winning research focused on the influence of age, male and female behavioral differences, and monoamine oxidase inhibitors intravenous nicotine self-administration responding, an animal model of tobacco smoking. At the University of Washington, Monica was a postdoctoral fellow in Psychiatry and Behavioral Sciences where she examined the role of phasic dopamine release in an in vivo rodent model of reward-based decision making.

Monica received her J.D. from the University of California, Irvine School of Law, where she received the “Best Outside Legal Counsel” award in the UCI Tech and Entrepreneurship Competition and the Pro Bono 1L achievement award.

Education

J.D., University of California, Irvine
Ph.D., Pharmacology and Toxicology, University of California, Irvine
B.S., Neuroscience, University of California, Los Angeles

Clerkship

U.S. District Court for the Central District of California

Awards

Best Outside Legal Counsel, UCI Tech and Entrepreneurship Competition
Pro Bono 1L achievement award, University of California School of Law
President’s Dissertation Year Fellowship, University of California, Irvine
Fellowship, Society for Neuroscience Scholars Program

Representative Cases

Tris Pharma v. Actavis Laboratories, No. 14-cv-01309 (D. Del.), aff’d No. 21-1495 (Fed. Cir.): secured key bench trial victory for plaintiff on validity and infringement for five patents covering Tris’ Quillivant XR® product, the first liquid long-acting treatment for ADHD. This ruling delays Actavis from commercializing its generic version until at least until 2031.

Media and Publications

Teva’s Copy of Tris’ QuilliChew ADHD Drug Blocked Under 2033, Bloomberg Law (Aug. 2022)

Actavis Loss In ADHD Drug IP Fight Backed By Fed. Circ., Law360 (July 2022)

Del. Judge Finds Teva Infringed ADHD Drug IP On Remand, Law360 (Dec. 2020)

Milbank Attys Assist Muslim Nonprofit in Cemetery Fight, Law360 (Nov. 2020)

Professional Affiliations

Howard Markey Inn of Court

Admissions

U.S. District Court for the Central District of California
State of California
U.S. Patent Office

LinkedIn

Monica Arnold

Monica Arnold
949.386.7264
monica.arnold@armondwilson.com

Monica Arnold is a trial attorney focused on IP litigation. Her work is technologically diverse, including genetically engineered cell therapies, and small molecule pharmaceuticals. Previously Monica clerked on the U.S. District Court for the Central District of California and was a litigation associate at Milbank LLP in Los Angeles.

Monica earned her B.S. in Neuroscience from the University of California, Los Angeles, where she utilized hydrogen peroxide exposure to the hippocampus to model effects of oxidative stress on synaptic plasticity in that brain region. She then received a Ph.D. in Pharmacology and Toxicology from the University of California, Irvine where her award-winning research focused on the influence of age, male and female behavioral differences, and monoamine oxidase inhibitors intravenous nicotine self-administration responding, an animal model of tobacco smoking. At the University of Washington, Monica was a postdoctoral fellow in Psychiatry and Behavioral Sciences where she examined the role of phasic dopamine release in an in vivo rodent model of reward-based decision making.

Monica received her J.D. from the University of California, Irvine School of Law, where she received the “Best Outside Legal Counsel” award in the UCI Tech and Entrepreneurship Competition and the Pro Bono 1L achievement award.

Education

J.D., University of California, Irvine
Ph.D., Pharmacology and Toxicology, University of California, Irvine
B.S., Neuroscience, University of California, Los Angeles

Clerkship

U.S. District Court for the Central District of California

Awards

Best Outside Legal Counsel, UCI Tech and Entrepreneurship Competition
Pro Bono 1L achievement award, University of California School of Law
President’s Dissertation Year Fellowship, University of California, Irvine
Fellowship, Society for Neuroscience Scholars Program

Representative Cases

Tris Pharma v. Actavis Laboratories, No. 14-cv-01309 (D. Del.), aff’d No. 21-1495 (Fed. Cir.): secured key bench trial victory for plaintiff on validity and infringement for five patents covering Tris’ Quillivant XR® product, the first liquid long-acting treatment for ADHD. This ruling delays Actavis from commercializing its generic version until at least until 2031.

Media and Publications

Teva’s Copy of Tris’ QuilliChew ADHD Drug Blocked Under 2033, Bloomberg Law (Aug. 2022)

Actavis Loss In ADHD Drug IP Fight Backed By Fed. Circ., Law360 (July 2022)

Del. Judge Finds Teva Infringed ADHD Drug IP On Remand, Law360 (Dec. 2020)

Milbank Attys Assist Muslim Nonprofit in Cemetery Fight, Law360 (Nov. 2020)

Professional Affiliations

Howard Markey Inn of Court

Admissions

U.S. District Court for the Central District of California
State of California
U.S. Patent Office